This is why you don't short retail favorites in a raging bull market.

$SIVE
NINGI RESEARCH: We are short $SIVE.

A retail-driven pump built on speculative hyperscaler links, a fabricated bottleneck narrative, and a rumored volume ramp-up has driven a 1,800%+ rally in $SIVE.ST.

Insiders sold ~29M shares into it. Here's what they're not telling you.👇 Full report:

Great take on $DLO by @realroseceline

Rose Celine Investments 🌹: Thoughts on $DLO

Investing is not always predictable, sometimes you get a perfect quarter and the stock goes up. Other times the numbers look messy underneath the surface even while the actual business keeps getting stronger. That is kind of how I look at this quarter from $DLO.

RT Investing visuals
The AI data center bottlenecks map & key players:

Demand:
• $MSFT
• $GOOGL
• $META
• $AMZN
• Leading LLM providers

Layer 1 - Systems & colocation:
• $DELL
• $HPQ
• $SMCI
• $EQIX
• $DLR

Layer 2A - Memory:
• $MU
• $HYNSE
• $SMSD

Layer 2B - Networking & optics:
• $AVGO
• $COHR
• $MRVL

Layer 2C - Power & cooling:
• $VRT
• $ETN
• $BE

Layer 3 - In-rack connectivity:
• $AVGO
• $ALAB
• $CRDO

Layer 4 - Foundry & packaging:
• $INTC
• $ASX
• $TSM
• $AMCR

Layer 5 - Semiconductor equipment:
• $ASML
• $AMAT
• $LRCX
• $KLAC

Note that this isn't an exhaustive list, but rather an overview of the most important businesses per segment.

I hope you found this breakdown insightful!

I've covered the supply chain in more detail in the article linked below.

Investing visuals: I just published my latest research article: The AI data center bottlenecks map, covering:

• The AI supply chain
• The key players at critical bottlenecks
• Where to look as constraints move down the supply chain

I loved diving into this over the past few weeks with the goal

$NVO Im biased and id still argue its deserved. After so many guidance cuts and 2026 negative growth forecasts it deserved a proper rerating.

Does not take anything away from the fact that I think its still a good longterm investment and risk/reward might be as good as it ever was

Hated Moats Investor: Wegovy pill numbers are more important than CagriSema "disappointment".

Should $NVO really be down YTD?

$NVO strong new data for the Wegovy pill presented!

TacticzHazel: $NVO Novo Nordisk presented strong new data for the Wegovy pill.

✅Early responders (about 29% of users) lost 21.6% of body weight by week 64
✅Even non-early-responders lost a meaningful 11.5%
✅77% of people with poor physical function saw significant improvement in mobility

$NVO Novo Nordisk presented strong new data for the Wegovy pill.

✅Early responders (about 29% of users) lost 21.6% of body weight by week 64
✅Even non-early-responders lost a meaningful 11.5%
✅77% of people with poor physical function saw significant improvement in mobility vs. 43% on placebo

They also dropped a comparison against $LLY's Orforglipron:

The Wegovy pill produced greater weight loss, and orforglipron users were about 14x more likely to quit due to GI side effects. (take this with a grain of salt as this is not H2H).

In a patient preference survey, 84% preferred a treatment profile matching Wegovy pill.

The headline trial result (OASIS 4) remains 17% average weight loss vs. 2.7% for placebo over 64 weeks.

RT TacticzHazel
$NVO Novo Nordisk presented strong new data for the Wegovy pill.

✅Early responders (about 29% of users) lost 21.6% of body weight by week 64
✅Even non-early-responders lost a meaningful 11.5%
✅77% of people with poor physical function saw significant improvement in mobility vs. 43% on placebo

They also dropped a comparison against $LLY's Orforglipron:

The Wegovy pill produced greater weight loss, and orforglipron users were about 14x more likely to quit due to GI side effects. (take this with a grain of salt as this is not H2H).

In a patient preference survey, 84% preferred a treatment profile matching Wegovy pill.

The headline trial result (OASIS 4) remains 17% average weight loss vs. 2.7% for placebo over 64 weeks.

RT Investing visuals
A breakdown of the photonics value chain and best positioned business:

Layer 1: Materials & wafers
• $GLW
• $AXTI
• $IQE
• $AIXA
• $AMS

Layer 2: Core photonic devices
• $IPGP
• $COHR
• $LITE
• $LASR
• $SIVE

• Layer 3: Components & modules
• $AAOI
• $MTSI
• $FN
• $VIAV
• $LPTH

Layer 4: Systems & equipment
• $ASML
• $BESI
• $ASM
• $LPKF
• $MKS

Layer 5: Test, metrology & yield
• $CAMT
• $FORM
• $AEHR
• $ONTO
• $VIAV

Investing visuals: Photonics stocks are going parabolic:

• $LITE +1621%
• $AAOI +1434%
• $COHR +529%
• $CRDO +377%
• $VIAV +353%
• $FN +281%
• $MTSI +189%
• $MRVL +186%
• $IPGP +136%
• $POET +127%

I agree with most of this post. Holding SaaS stocks right now seems like the clearest example of opportunity cost.

With the Long Semis/short SaaS trade in full throttle, SaaS stocks have been getting hammered across the board.

And that certainly hit the returns of investors with strong SaaS exposure.

I do however think that building some exposure to SaaS is not a bad idea at all. Having some weighting towards a beaten down and arguably cheapish sector can do wonders in the long-term.

But I do agree, especially if you're a bit more medium-term focused, that riding strong-sentiment stocks in the AI-buildout was the more sensible play.

And argubly, still is the best play until proven otherwise.

Therefore, I do both. Having exposure to both segment s is the balanced way to do it.

And lastly, part of the opportunity argument is always hindsight bias.

I don't think any SaaS investors held their stocks thinking/knowing it would go down like this.

That's just the way the market works. Sometimes you are right, and sometimes you are not.

Anyway, food for thought and reflection.

Babyfolio: A lot of software stocks enthusiasts on X.
Let me tell you about a lesson I learned the hard way(and hopefully you won't have to).

This applies to most(if not all) software stocks at the moment.

Sometimes, being too early is just being wrong, those who are invested and try so

Cycling the Alpe d'Huez in a fight against cancer. Jan is doing it. And he needs all the support he can get.

Check out his story below and donate if you can. 😘

Investing visuals: A fight against cancer.

I’d like to share something very personal: on June 4, I’ll be cycling the Alpe d’Huez to raise money for the KWF Dutch Cancer Society.

Beyond the athletic challenge it brings, I’m taking part because cancer is something that affects me personally.

My

RT Investseekers
$NVO oral Wegovy prescription numbers:

After the slight decline last week, we are now back to weekly growth.

This is how insured prescriptions have developed week over week since launch (Symphony data):

4,290 → 20,382 → 26,794 → 29,410 → 38,423 → 54,038 → 58,586 → 60,680 → 67,145 → 70,151 → 72,165 → 76,389 → 77,903 → 79,854 → 87,186 → 85,155 → 90,512

Note that the first figures reported in the media are often slightly below the final Symphony numbers.

Symphony data.

#stocks #Investing

What do you think?

Long SaaS, Short Semis for the upcoming months?

TacticzHazel: I think it's time to cut exposure to Semis / AI buildout companies.

I think a lot of people on here will disagree, but hear me out.

The run-up in memory stocks, photonics and semis has been spectacular, and it's been great to watch.

The attention on X has been spot-on, and a